Based on these results, Margetuximab has received FDA approval for treating HER2-low metastatic BC along with chemotherapy for patients who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease [75]. The gene discussed is ERBB2; the disease is metastatic neoplasm.